Skip to main content
OpenTrials
Completed

NCT Number: NCT03375957

Sensitization Study of ATx201 in Healthy Volunteers

This is a Phase I, single-site study to evaluate the sensitization potential of topically applied ATx201 GEL, 2% and 4%, along with a placebo control, in healthy human subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Bio-Kinetic Clinical Applications, LLC

Springfield, Missouri, 65802, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Good general health
  • Body Mass Index no less than 19.0 and no greater than 36.0 kg/m² (inclusive).
  • Demonstrates a Fitzpatrick skin score of I - IV
  • Female subjects must agree to use acceptable contraceptive methods from the Screening Visit through 90 days after the End of Study (EOS) Visit; or postmenopausal status with no menses for at least 1 year prior to the Screening Visit.
  • Willing to refrain from excessive consumption of sodium in food or beverage 48 hours prior to Day 1 through EOS Visit.
  • Willing to shower using the same non-medicated soap/cleansers, and abstain from excessive sun exposure (including tanning salons) from the Screening Visit through EOS Visit.

Exclusion criteria

  • Reports a history of diabetes mellitus, clinically significant asthma (acceptable if no episode within 5 years prior to Day 1), or currently diagnosed with hypertension or circulatory disease.
  • Reports use of any oral, nasal or topical corticosteroids, or oral or topical retinoids (other than Vitamin A at normal dietary amounts)
  • Reports a significant history of allergy to soaps, lotions, emollients, ointments, creams, cosmetics, adhesives, or latex.
  • Reports a history of significant skin conditions or disorders such as psoriasis, atopic dermatitis, etc.
  • Reports a history of significant dermatologic cancers.
  • Displays an obvious difference in skin color between upper arms or upper back or the presence of a skin anomaly
  • Reports smoking or use of tobacco or nicotine delivery products within 14 days prior to Day 1 through EOS Visit.
  • Presence of any clinically significant results from laboratory tests and vital signs assessments, as judged by the Investigator.
  • A female who is pregnant, lactating, breastfeeding, or intends to become pregnant over the course of the study.
  • Reports a history of drug or alcohol addiction or abuse within the past year.
  • Reports having donated blood or plasma within 48 hours prior to Day 1 through EOS Visit.
  • Subject exhibits excessive hair density on the upper arms or back such that patch adhesion could be compromised.
  • Subject reports undergoing hair depilation (e.g. chemical, laser, physical) within 30 days prior to Day 1 through EOS Visit.

Treatment and study plan

ATx201

Drug

two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms

ATx201 Placebo Gel

Drug

two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms

Primary outcomes

  1. Dermal Response Score

    Time frame: 21 days

    number of patients with a dermal response score of at least 2

Secondary outcomes

  1. Dermal Response and Effects Score

    Time frame: 21 days

    number of patients with a dermal response and effects score of at least 3

Sponsors and collaborators

Lead sponsor

UNION therapeutics

Industry

Registry information

Official study title

A Single-Site Study To Evaluate the Sensitization Potential of Topically Applied ATx201 in Healthy Human Volunteers

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Dec 18, 2017
Registry last updated
May 7, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.